| 10.71 0.11 (1.04%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.35  |
1-year : | 14.27 |
| Resists | First : | 11.43 |
Second : | 12.22 |
| Pivot price | 10.75 |
|||
| Supports | First : | 10.17 | Second : | 8.46 |
| MAs | MA(5) : | 10.64  |
MA(20) : | 10.76 |
| MA(100) : | 10.06 |
MA(250) : | 9.96 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 52.2 |
D(3) : | 47.1 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 14 | Low : | 6.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TIL ] has closed above bottom band by 45.7%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.72 - 10.77 | 10.77 - 10.81 |
| Low: | 10.32 - 10.38 | 10.38 - 10.42 |
| Close: | 10.62 - 10.72 | 10.72 - 10.79 |
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Fri, 12 Apr 2024
Jefferies cuts Instil Bio to hold, cites drug discontinuation (NASDAQ:TIL) - Seeking Alpha
Fri, 12 Apr 2024
Jefferies downgrades Instil Bio stock, cites clinical development halt By Investing.com - Investing.com
Wed, 27 Mar 2024
What Makes Instil Bio (TIL) a New Buy Stock - Yahoo Finance
Thu, 21 Mar 2024
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Thu, 18 Jan 2024
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why - Yahoo Finance
Tue, 16 Jan 2024
Instil Bio Announces Strategic Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 65.9 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | -24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.1 % |
| Return on Equity (ttm) | -53 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -0.45 |
| PEG Ratio | 0 |
| Price to Book value | 0.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|